LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Dovitinib | 0.04 | uM | LJP5 | 3 | E24 | 72 | hr | 1476 | 2575 | 3796 | 0.6782 | 0.5040 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 1 | E23 | 72 | hr | 1476 | 3073 | 3788 | 0.8111 | 0.7145 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 2 | E23 | 72 | hr | 1476 | 2867 | 3731 | 0.7684 | 0.6424 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 3 | E23 | 72 | hr | 1476 | 2514 | 3796 | 0.6622 | 0.4778 |
| SK-BR-3 | Dovitinib | 0.37 | uM | LJP5 | 1 | E22 | 72 | hr | 1476 | 2438 | 3788 | 0.6435 | 0.4461 |
| SK-BR-3 | Dovitinib | 0.37 | uM | LJP5 | 2 | E22 | 72 | hr | 1476 | 2359 | 3731 | 0.6322 | 0.4195 |
| SK-BR-3 | Dovitinib | 0.37 | uM | LJP5 | 3 | E22 | 72 | hr | 1476 | 2738 | 3796 | 0.7212 | 0.5733 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 1 | E21 | 72 | hr | 1476 | 2647 | 3788 | 0.6987 | 0.5363 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 2 | E21 | 72 | hr | 1476 | 2548 | 3731 | 0.6829 | 0.5037 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 3 | E21 | 72 | hr | 1476 | 2518 | 3796 | 0.6632 | 0.4795 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 1 | E20 | 72 | hr | 1476 | 1919 | 3788 | 0.5065 | 0.2126 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 2 | E20 | 72 | hr | 1476 | 1894 | 3731 | 0.5076 | 0.2046 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 3 | E20 | 72 | hr | 1476 | 2051 | 3796 | 0.5402 | 0.2727 |
| SK-BR-3 | Dovitinib | 10 | uM | LJP5 | 1 | E19 | 72 | hr | 1476 | 1831 | 3788 | 0.4833 | 0.1714 |
| SK-BR-3 | Dovitinib | 10 | uM | LJP5 | 2 | E19 | 72 | hr | 1476 | 1583 | 3731 | 0.4243 | 0.0533 |
| SK-BR-3 | Dovitinib | 10 | uM | LJP5 | 3 | E19 | 72 | hr | 1476 | 1732 | 3796 | 0.4562 | 0.1242 |
| SK-BR-3 | GSK 690693 | 0.04 | uM | LJP5 | 1 | F24 | 72 | hr | 1476 | 2744 | 3788 | 0.7243 | 0.5775 |
| SK-BR-3 | GSK 690693 | 0.04 | uM | LJP5 | 2 | F24 | 72 | hr | 1476 | 2748 | 3731 | 0.7365 | 0.5911 |
| SK-BR-3 | GSK 690693 | 0.04 | uM | LJP5 | 3 | F24 | 72 | hr | 1476 | 2331 | 3796 | 0.6140 | 0.3980 |
| SK-BR-3 | GSK 690693 | 0.12 | uM | LJP5 | 1 | F23 | 72 | hr | 1476 | 2680 | 3788 | 0.7074 | 0.5503 |
| SK-BR-3 | GSK 690693 | 0.12 | uM | LJP5 | 2 | F23 | 72 | hr | 1476 | 2668 | 3731 | 0.7151 | 0.5563 |
| SK-BR-3 | GSK 690693 | 0.12 | uM | LJP5 | 3 | F23 | 72 | hr | 1476 | 2430 | 3796 | 0.6400 | 0.4414 |
| SK-BR-3 | GSK 690693 | 0.37 | uM | LJP5 | 1 | F22 | 72 | hr | 1476 | 2826 | 3788 | 0.7459 | 0.6120 |
| SK-BR-3 | GSK 690693 | 0.37 | uM | LJP5 | 2 | F22 | 72 | hr | 1476 | 2461 | 3731 | 0.6596 | 0.4651 |
| SK-BR-3 | GSK 690693 | 0.37 | uM | LJP5 | 3 | F22 | 72 | hr | 1476 | 2529 | 3796 | 0.6661 | 0.4843 |